Free Case Evaluation

You must read the following notice before sending an e-mail message to Robins Kaplan LLP.

Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.

If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.

By accepting these terms, you are confirming that you have read and understood this important notice.

Thank you, your message has been sent. Please allow 24 hours for a response.

Consumer Alert: Popular Anti-Nausea Drug Zofran Linked to Birth Defects

Zofran is an anti-nausea drug not FDA-approved for use during pregnancy, but often prescribed "off label" for morning sickness. It is associated with an increased risk of cleft palate and congenital heart defects.1

M. Anderka et al. Medications Used to Treat Nausea and Vomiting of Pregnancy and Risk of Selected Birth Defects. Birth Defects Res A Clin Mol Teratol. (Jan. 2012); JT Anderson et al. Ondansetron use in Early Pregnancy and the Risk of Congenital Malformations – A Register Based Nationwide Cohort Study. Pharmacoepidemiology and Drug Safety. (Oct. 2013)

Back to Top